Novo Nordisk objects to proposed reimbursement change for its fast-acting insulin in Denmark
![Photo: Tidsvilde Stine/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13450252.ece/ALTERNATES/schema-16_9/20160929-062241-pf-1920x1080we.jpg)
The Reimbursement Committee, which advises the the Danish Medicines Agency on drug reimbursements, has proposed a reassessment of the drug Fiasp, and the company behind the product, Novo Nordisk, has voiced its opposition to the change.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk Q3 profit surpasses USD 1.8bn
For subscribers
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers